Development and Validation of a Model to Predict Growth of Potentially Antibiotic-Resistant Gram-Negative Bacilli in Critically Ill Children With Suspected Infection

Todd Karsies, Melissa Moore-Clingenpeel, and Mark Hall

Background. Risk-based guidelines aid empiric antibiotic selection for critically ill adults with suspected infection with Gram-negative bacilli with high potential for antibiotic resistance (termed high-risk GNRs). Neither evidence-based guidelines for empiric antibiotic selection nor validated risk factors predicting high-risk GNR growth exist for critically ill children. We developed and validated a model for predicting high-risk GNR growth in critically ill children with suspected infection.

Methods. This is a retrospective cohort study involving 2 pediatric cohorts admitted to a pediatric intensive care unit (ICU) with suspected infection. We developed a risk model predicting growth of high-risk GNRs using multivariable regression analysis in 1 cohort and validated it in a separate cohort.

Results. In our derivation cohort (556 infectious episodes involving 489 patients), we identified the following independent predictors of high-risk GNR growth: hospitalization >48 hours before suspected infection, hospitalization within the past 4 weeks, recent systemic antibiotics, chronic lung disease, residence in a chronic care facility, and prior high-risk GNR growth. The model sensitivity was 96%, the specificity was 48%, performance using the Brier score was good, and the area under the receiver operator characteristic curve (AUROC) was 0.722, indicating good model performance. In our validation cohort (525 episodes in 447 patients), model performance was similar (AUROC, 0.733), indicating stable model performance.

Conclusions. Our model predicting high-risk GNR growth in critically ill children demonstrates the high sensitivity needed for ICU antibiotic decisions, good overall predictive capability, and stable performance in 2 separate cohorts. This model could be used to develop risk-based empiric antibiotic guidelines for the pediatric ICU.

Keywords. drug resistance; risk factors; pediatric intensive care unit; Gram-negative bacterial infections; critical illness.

Timely administration of empiric antibiotics to which the infecting pathogen is susceptible is a hallmark of successful management of suspected infections in critically ill adults and children. Failure to provide prompt, correct empiric antibiotics is associated with adverse outcomes in many conditions, including adult and pediatric septic shock, adult ventilator- and health care–associated pneumonia, and severe community-acquired pneumonia (CAP) in adults and children [1–8].

This is balanced against rising antibiotic resistance in health care [9]. Particularly concerning in critical care is rising resistance among Gram-negative bacilli (GNRs) such as Pseudomonas sp., Klebsiella sp., and Stenotrophomonas sp. This has made appropriate antibiotic selection more challenging in the setting of infection with these organisms, which are at high risk of being resistant to typical antibiotics that target GNRs [10–12]. We term these organisms “high-risk GNRs.” Prescribing extremely broad-spectrum antibiotics to intensive care unit (ICU) patients with suspected infection may ensure initial empiric correctness but would unnecessarily expose patients to medication side effects and could accelerate development of antibiotic resistance.

To allow both antibiotic stewardship and the need for early, correct empiric antibiotics, guidelines have been developed to aid antibiotic selection for adults with suspected infection [13–15]. These use risk stratification for infection by potentially resistant bacteria and provide antibiotic choices based on these risk factors. Pediatric guidelines exist for CAP but do not address the potential for high-risk GNRs [16]. No clear guidelines exist for antibiotic selection in other severe pediatric infections (eg, sepsis, health care–associated pneumonia, and ventilator-associated pneumonia) in the United States.

There is a paucity of literature regarding factors associated with high-risk GNRs in children and no statistical models that predict increased risk for these pathogens [17, 18]. Such a model could aid in the development and testing of empirical antimicrobial prescribing strategies in critically ill children. We recently reported that nearly half of children admitted to our pediatric ICU (PICU) with cultures positive for a high-risk GNR presented from the community without recent hospital exposure...
Thus, strategies targeting these organisms only in nosocomial infections may lead to inappropriately narrow-spectrum empiric antibiotics in many patients with high-risk GNRs. We therefore conducted a retrospective cohort study to develop and validate a model for predicting growth of high-risk GNRs in clinical cultures from critically ill children using our previously published risk factors as a starting point.

**METHODS**

This study was conducted in the PICU at Nationwide Children’s Hospital, a large quaternary care children’s hospital with services including oncology, bone marrow transplantation, and solid organ transplantation. Data from a separate cardiothoracic ICU were not included. Data were collected from the electronic health record and represent temporally distinct derivation and validation data sets. The Institutional Review Board of Nationwide Children’s Hospital approved this study with a waiver of informed consent.

**Definitions**

High-risk GNRs included *Pseudomonas*, *Acinetobacter*, *Enterobacter* species, *Klebsiella oxytoca*, extended-spectrum β-lactamase-producing species, and other GNRs that demonstrated resistance or intermediate susceptibility to antibiotics from more than 1 antibiotic class expected to cover these organisms. These selections were based on previous literature highlighting organisms for which antibiotic resistance was of particular concern and also on local antibiotic susceptibility patterns [11–13]. Immunosuppression was defined as having 1 or more of the following: malignancy, chemotherapy within the prior month, solid organ transplant, nonengrafted stem cell transplant, chronic immunosuppressive therapy, chronic corticosteroid therapy (≥0.5 mg/kg/d prednisone equivalent or ≥10 mg/d), acute corticosteroid therapy for >5 days in the past month, or underlying congenital or acquired immunodeficiency.

**Derivation Cohort**

For model derivation, we used our previously published cohorts, which were used to evaluate the impact of a PICU empiric antibiotic prescribing protocol [19]. These included subjects from all of 2004 (pre-protocol implementation) and 2007 (post-protocol implementation). All subjects had at least 1 culture obtained and were admitted to the PICU with suspected infection. Subjects were identified for screening using infection-related International Classification of Diseases, Ninth Revision (ICD-9) codes including those for sepsis, bacteremia, meningitis, tracheitis, pneumonia, and urinary tract infection. Only patients for whom intent to treat infection in the PICU was confirmed by record review were included. Multiple episodes could be included for a single patient if 2 investigators agreed that the episode represented new symptoms concerning for new infection.

**Validation Cohort**

For model validation, we created a new cohort that included all patients with at least 1 culture obtained who were admitted to the same PICU with suspected infection using identical infection-related ICD-9 codes over a later 1-year period (July 1, 2014, to June 30, 2015). Only patients for whom intent to treat infection in the PICU was confirmed by record review were included. Multiple episodes could be included for a single patient if the subsequent episode occurred off antibiotics (except prophylactic antibiotics) and involved new onset of symptoms concerning for infection. The requirement for symptoms occurring off antibiotics was added for the validation cohort both to make our inclusion more rigorous with regard to ensuring we were capturing distinct infectious episodes and to streamline our process for identifying these separate episodes.

**Potential Predictors**

We evaluated our published risk factors for inclusion as predictors for high-risk GNRs in critically ill children [19]. These included hospitalization >48 hours before onset of suspected infection; current or recent use of systemic antibiotics (>7 days within the past 6 weeks); chronic lung disease, including chronic structural lung disease (eg, cystic fibrosis, bronchopulmonary dysplasia) plus chronic mechanical ventilation other than nocturnal ventilation for obstructive sleep apnea; unrepaired or incompletely palliated congenital heart disease; immunosuppression (see earlier definition); residence in a chronic care facility; inpatient hospitalization within the past month; presence of an indwelling central venous catheter; prior history of high-risk GNRs; or history of prematurity in children <2 years old. Children with any previous positive culture with growth of high-risk GNRs were considered to meet the definition of prior history of high-risk GNRs. Due to suspicion that infants and patients admitted for viral respiratory infection might be at lower risk compared with others with similar risk factors, we included age <1 year and having viral testing done as potential protective factors.

**Outcome Variable**

The outcome used for model construction was growth of any high-risk GNR in cultures obtained at the onset of suspected infection from blood, urine, cerebrospinal fluid, pleural fluid, peritoneal fluid, abscess fluid, or the lower respiratory tract (tracheal aspirate, protected brush tracheal aspirate, bronchoalveolar lavage specimen).

**Data Collection**

In addition to the presence of predictors plus culture and susceptibility data for each episode, we collected data on age, sex, and illness severity at the time of ICU admission using the Pediatric Risk of Mortality III (PRISM III) score [20].

**Sample Size Estimate**

For our derivation cohort, we used our previously published cohort, which contained 556 infectious episodes, with 139 episodes growing high-risk GNRs. For validation, based on prior literature, we determined a need for at least 100 episodes with
growth of high-risk GNRs and at least 100 episodes without these pathogens to ensure adequate model power [21, 22]. In addition, based on this number and using the prevalence of high-risk GNRs found in our derivation cohort (25%), we estimated that we would have 80% power to estimate a target AUC of 0.7 (found in our derivation cohort) with a confidence interval width of ±0.06. To capture potential seasonal variability, we evaluated all patients for 1 calendar year, which comprised 525 infectious episodes and 114 episodes with high-risk GNRs. There were no missing data from either cohort for model development.

Model Development
We used multivariable logistic regression with backward stepwise selection to develop our prediction model. Candidate variables included the 12 potential predictors outlined above. Variables were removed if they did not significantly impact model goodness of fit, as assessed by Akaike's Information Criterion. Because a main goal was to develop a simple model that was straightforward for bedside use, we did not assess interactions or nonlinearity. The final model regression formula was transformed into a simpler score formula by scaling and rounding regression coefficients. A total score was calculated for each patient by summing each model variable's score. We further simplified the model by determining the optimal score threshold that would result in at least 95% sensitivity. This was used to classify patients as being at increased risk for high-risk GNRs vs low risk for high-risk GNRs. We selected a 95% sensitivity cutoff based on physician risk tolerance, with our local physician group being willing to prescribe inappropriately narrow empiric antibiotics to no more than 5% of critically ill patients with suspected infection.

Model performance at the derivation stage was evaluated for a model using the risk score and another using the simplified binary risk status. Area under the receiver operating characteristic curve (AUROC) was used to assess discrimination (ability to separate patients who grew a high-risk GNR from those who did not). Model calibration (concordance between predicted and true GNR status) was assessed using the Brier score. Sensitivity and specificity are also reported. As a sensitivity analysis, we repeated model derivation and performance assessments using only the initial episode per patient to rule out any differential influence of patients with multiple episodes.

We assessed internal validity using a bootstrap procedure to estimate the amount performance statistics might differ given a different sample. For bootstrap validation, 1000 samples of size n = 556 (size of derivation cohort) were drawn, each with replacement. The entire model derivation process (including variable selection and simplification) was repeated in each bootstrap replicate, and the resulting model performance parameters were recorded. Optimism (or bias) in the original sample was estimated by taking the difference between the original performance parameter and the mean of the bootstrap sampling distribution of that parameter.

Model Validation
Patients in the validation cohort were classified as being at high or low risk for high-risk GNRs based on the risk group found during model development. We then calculated the sensitivity, specificity, positive predictive value, negative predictive value, and AUROC for predicting high-risk GNR status in the new cohort. To evaluate the potential impact on antibiotic utilization, we compared the number of patients considered high risk (thus warranting empiric broad antipseudomonal antibiotics) for both our previously published 10-item risk factor set and our new 6-item set.

Analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC) and R: A language and environment for statistical computing 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
A total of 556 infectious episodes from 489 patients were included in the derivation cohort, whereas 525 episodes from 447 patients were included in the validation cohort. Patient characteristics and risk factor distribution are shown in Table 1. A minority developed infection while hospitalized (169 [30%] of the derivation cohort and 151 [29%] of the validation cohort); most had suspected infection at hospital admission. The types of bacteria identified are shown in Table 2, and sites from which

| Table 1. Population Characteristics and Risk Factors |
|---------------------------------------------------|
| **Baseline characteristics**                      |
| Age, y<sup>b,c</sup>                              | 4 (0.75–14)  | 5 (0.75–13) |
| Male sex<sup>b</sup>                              | 249 (51)     | 242 (54)    |
| Admission PRISM II<sup>b,c</sup>                  | 5 (2–10)     | 6 (2–11)    |
| **Risk factors**                                  |
| Hospital >48 h                                    | 169 (30)     | 151 (29)    |
| Recent antibiotics                                | 146 (26)     | 145 (28)    |
| Chronic lung disease                              | 80 (24)      | 92 (18)     |
| Congenital heart disease                          | 42 (8)       | 7 (1)       |
| Immunosuppressed                                  | 59 (11)      | 94 (18)     |
| Chronic care facility                             | 24 (4)       | 23 (4)      |
| Prior high-risk GNRs                              | 146 (26)     | 125 (24)    |
| Recent hospitalization                            | 96 (17)      | 75 (14)     |
| Central venous line                               | 31 (6)       | 110 (21)    |
| Prematurity                                       | 13 (2)       | 34 (6)      |
| Age <1 y                                          | 172 (32)     | 140 (27)    |
| Viral testing                                     | 203 (37)     | 385 (73)    |
| **Outcomes**                                      |
| Culture +                                         | 323 (58)     | 325 (62)    |
| High-risk GNR +                                   | 139 (25)     | 114 (22)    |

Data are reported on a per-episode basis unless otherwise noted. Values are reported as No. (%) unless otherwise noted.

Abbreviations: GNR, Gram-negative bacilli; PRISM III, Pediatric Risk of Mortality III.

<sup>1</sup>Number of infectious episodes.

<sup>2</sup>Data are per patient (n = 489 for the derivation cohort and 447 for the validation cohort).

<sup>3</sup>Expressed as median (interquartile range).
positive cultures were obtained are shown in the Supplementary Data (Supplementary Table 1).

Six factors were independently associated with growth of high-risk GNRs in the derivation cohort—hospitalization for >48 hours before onset of suspected infection, hospitalization within the past 4 weeks, recent treatment with systemic antibiotics, presence of chronic lung disease, residence in a chronic care facility, and having previously grown high-risk GNRs. These final variables from our derivation cohort, including coefficients, odds ratios, and confidence intervals, are shown in Table 3, as is the risk score for each risk factor derived from our regression formula.

The initial complete regression model before stepwise selection, as well as univariate associations, is shown in Supplementary Table 2. The optimal score threshold resulting in a minimum model sensitivity of 95% was 35.5, meaning that patients would be considered at elevated risk for high-risk GNRs if they had any model risk factors. Therefore, for simplification binary risk classification, patients with any variable from Table 3 (individually or in combination) were considered at

| Risk Factor | Coefficient | OR  | Lower CL | Upper CL | PValue | Score |
|-------------|-------------|-----|----------|----------|--------|-------|
| Intercept   | −2.8004     |     |          |          |        |       |
| Hospital >48 h | 1.3785  | 3.969 | 2.299 | 6.853   | <.0001 | 100   |
| Recent antibiotics | 0.8433 | 2.324 | 1.421 | 3.802   | .0008  | 61    |
| Chronic lung disease | 1.1899 | 3.287 | 1.735 | 6.225   | .0003  | 86    |
| Chronic care facility | 1.3091 | 3.703 | 1.387 | 9.887   | .009   | 95    |
| Prior high-risk GNRs | 1.2029 | 3.33  | 2.005 | 5.529   | <.0001 | 87    |
| Recent hospitalization | 1.0151 | 2.76  | 1.543 | 4.936   | .0006  | 74    |

Abbreviations: CL, confidence limit; GNR, Gram-negative bacilli; OR, odds ratio.

DISCUSSION

Using 2 large, independent PICU cohorts, we have developed and validated a predictive model for growth of high-risk GNRs in critically ill children with suspected infection. This model is simple to use, provides the high sensitivity needed for empiric antibiotic selection in critically ill patients, and maintains enough specificity to limit unnecessarily broad antibiotics for many PICU patients. Our internal and external validation demonstrated that our risk model is not overfitted; the performance in the validation cohort was nearly identical to the derivation cohort despite being separated by nearly 10 years.

This study focuses on the epidemiology of pathogen growth in culture, not the presence or absence of infection. Adjudication of true infection can be difficult in critical illness, and it was not our intent to differentiate infection from colonization [23]. Rather, we intend to provide clinicians a tool to gauge a potentially infected patient’s risk for harboring high-risk GNRs. If the clinician decides to treat empirically based on clinical judgment, this tool could guide more informed antibiotic prescription.

To our knowledge, this is the first validated predictive model for high-risk GNRs in critically ill children with suspected infection. The identified risk factors are objective and easily measured. Prior studies have evaluated risk of hospital-acquired
infection, risk of colonization with these pathogens, or have evaluated antibiotic strategies using nonvalidated risk factors [19, 24–27]. Given the lack of PICU-specific guidelines, validated risk factors are important to aid empiric antibiotic selection and stewardship. Early correct empiric antibiotics can improve outcomes in critically ill children with suspected infection, whereas antibiotic stewardship is equally important to limiting development of antibiotic resistance. This balance is discussed in the recent adult ventilator-associated pneumonia guidelines [6, 8, 14]. Our validated risk factors could serve as a foundation for empiric antibiotic strategies in critically ill children, taking into account both these concerns by restricting broad antipseudomonal antibiotics to only those determined more likely to grow high-risk GNRs rather than basing these antibiotic decisions on illness severity.

Use of clinical factors to aid risk assessment for specific pathogens is a component of many antibiotic guidelines, including adult guidelines for community- and hospital-acquired pneumonia [13–15]. Guideline-concordant antibiotic strategies can improve outcomes for critically ill adults [28–31]. Unfortunately, all current evidence-based ICU guidelines are for adults. This can lead to practice variability and inappropriate empiric antibiotic prescribing for critically ill children, which could worsen outcomes if empiric antibiotics are inappropriately narrow or increase antibiotic resistance, side effects, and cost if empiric coverage is too broad.

Our validated risk factors could be utilized to evaluate PICU-specific empiric antibiotic strategies. We have integrated these risk factors into antibiotic order sets, allowing risk assessment at initial antibiotic prescription. We previously showed that this strategy (with a broader risk factor set) improved empiric antibiotic appropriateness in our PICU [19]. Our current results imply that we could safely restrict empiric antipseudomonal agents further beyond our previously published strategy, which already provided a significant antibiotic stewardship benefit compared with an approach prescribing these very broad antibiotics to all critically ill patients based on illness severity. Given the success of adult guidelines, the success of our local guideline implementation, and the broader success of pediatric CAP guidelines in non-ICU patients, it seems reasonable to expect that similar risk-based strategies could improve the care of critically ill children with suspected infection [19, 28–34]. For these patients, current evidence suggests that there are opportunities for improvement both in prescribing broader-spectrum antibiotics for some patients and in prescribing narrower-spectrum agents for others [6, 8, 35]. We envision that our risk model could be incorporated into PICU empiric antibiotic strategies for an individual unit or as part of consensus antibiotic use strategies either as we have proposed (a single yes/no decision) or through calculation of individual risk for high-risk GNRs using individual model scores.

There are many strengths of our study and of our risk model. Our cohorts were large (particularly for a PICU study) and representative of a multidisciplinary PICU population. The risk factors were clearly defined and easily determined, and the outcome was concrete and objective. Our findings were statistically robust, and the model performed well in distinct populations separated by time. Our final model is simple to apply at the time of initial antibiotic selection and provides a yes/no prediction rather than requiring calculation and interpretation of a risk score. Although this can limit the nuance of a score, ease of use may enhance clinical feasibility. Our cohorts contained many children with complex conditions. Leyenaar et al. pointed out antibiotic challenges in these patients and proposed evaluation of similar antibiotic selection strategies in this group [36]. Further research is needed to evaluate our risk factor strategy for these children outside the PICU.

There are several limitations of our study. All patients were from a single center, potentially limiting the generalizability to other ICUs. It will be important to validate the risk model in a multicenter fashion. In addition, the risk factor prevalence in our cohorts may differ from other ICUs, and indeed, it differed between our derivation and validation cohorts. The stable model performance between our cohorts is reassuring in

| Statistic | Derivation | Bias | Validation | Derivation | Bias | Validation |
|-----------|------------|------|------------|------------|------|------------|
| AUC       | 0.72 (0.69–0.75) | –0.024 | 0.72 (0.69–0.75) | 0.73 (0.70–0.77) | –0.051 | 0.74 (0.70–0.78) |
| Brier     | 0.16 (0.15–0.17) | 0.004 | 0.14 (0.12–0.16) | 0.006 |
| Sensitivity | 0.96 (0.93–1.0) | –0.019 | 0.93 (0.88–0.98) | 0.95 (0.89–0.98) | –0.014 | 0.91 (0.82–0.96) |
| Specificity | 0.48 (0.43–0.53) | –0.03 | 0.51 (0.46–0.56) | 0.52 (0.47–0.57) | –0.087 | 0.58 (0.53–0.63) |
| PPV       | 0.38 (0.33–0.43) | –0.021 | 0.35 (0.29–0.40) | 0.34 (0.28–0.39) | –0.025 | 0.34 (0.28–0.40) |
| NPV       | 0.98 (0.95–1.0) | –0.016 | 0.93 (0.94–0.99) | 0.98 (0.95–1.0) | –0.017 | 0.96 (0.94–0.99) |

*Sensitivity analysis, including only the first infectious episode per patient.*
this regard. Our cohorts had limited representation from some key populations, including those with congenital heart disease (1% of our validation cohort). This could limit generalizability, although this risk factor was not associated with growth of high-risk GNRs in the derivation cohort, which had a higher proportion of these patients. Interestingly, immunocompromise was not independently associated with growth of high-risk GNRs, perhaps because other better-performing risk factors were frequently in this population (eg, current or recent hospitalization [59%], recent systemic antibiotics [37%], prior high-risk GNRs [19%]). Additionally, a significant portion of our cultures were respiratory cultures, potentially skewing our model results due to over-representation. However, our breakdown of culture sources reflects typical ICU experience and is likely representative of infections encountered in the PICU [37]. Additionally, although some of our risk factors may seem obvious (prescribing antibiotics that cover high-risk GNRs to patients who have previously grown high-risk GNRs), our local experience is that prior microbiologic data are not always considered when making antibiotic decisions. Any model that excludes these obvious factors would be woefully incomplete.

Although the model had high sensitivity, the specificity was lower, resulting in AUROCs that were 0.722 and 0.720 for the derivation and validation cohorts, respectively. We suspect that specificity suffered because some subjects had negative cultures due to an inability to sample the likely true site of infection (eg, the lower respiratory tract in children receiving noninvasive ventilatory support). This could lead to an underestimate of specificity and a bias against our model through assignment of false negatives. Research is ongoing to evaluate the impact of these patients on model performance. A predictive model would have particular utility in this or other populations in which there are inadequate microbiologic data to guide antibiotic de-escalation. Also, we do report positive and negative predictive values for our cohorts, but it is important to note that these may differ in other populations because they depend on the prevalence of the outcome.

We suspected that infants and those with suspected viral infections would have reduced risk for growth of high-risk GNRs but were unable to demonstrate this, potentially due to sample size. Similarly, duration of hospitalization prior to infection was only available as a binary risk factor for the derivation cohort. This prevented us from evaluating the timing during a hospitalization at which increased risk for growth of high-risk GNRs may occur. Further studies are needed to further refine our risk factors related to these issues.

CONCLUSIONS

Antibiotic selection and management of suspected infections in the PICU require a balance between the need for timely antibiotics in critically ill patients and the need for good antibiotic stewardship. Our risk factor model provides a simple tool that effectively stratifies critically ill children with suspected infection into those at increased risk for growing high-risk GNRs and those for whom the risk is low. Further research is needed to validate these risk factors in other institutions and to evaluate their potential impact on broad-spectrum antibiotic utilization and patient outcomes in a multicenter fashion.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

Financial support. This study was unfunded.

Conflict of interest. T.K. has no conflicts of interest to declare. M.M.C. has no conflicts of interest to declare. M.H. has no conflicts of interest to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589–96.
2. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045–53.
3. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care Med 2006; 34:1011.
4. Garnacho-Montero J, García-Garmendia JL, Barrero-Almadorov A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:24–52.
5. Hamandi B, Holbrook AM, Humar A, et al. Delay of adequate empiric antibiotic therapy is associated with increased mortality among solid-organ transplant patients. Am J Transplant 2009; 9:1657–65.
6. Muszynski JA, Knatz NL, Sargel CL, et al. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J 2011; 30:295–301.
7. Rodriguez-Baño J, Millán AB, Domínguez MA, et al; GEIH/GEMARA/REIPI. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. J Infect 2009; 58:131–7.
8. Weiss SL, Fitzgerald JC, Balamuth F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 2014; 42:2409–17.
9. Scutti S. The world is running out of antibiotics, WHO says. CNN.com. September 19, 2017. http://www.cnn.com/2017/09/19/health/antibiotic-resistance-who/index.html. Accessed October 11, 2017.
10. Kollef MH. Gram-negative bacterial resistance: evolving patterns and treatment paradigms. Clin Infect Dis 2005; 40(Suppl 2):S85–8.
11. Kollef MH, Golan Y, Mickel ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections—proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 2011; 53(Suppl 2):S33–55; quiz S6–8.
12. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1–12.
13. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171(4):888–416.
14. Kallí AC, Metzersky ML, Klompas M, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:575–82.
15. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27–72.
16. Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25–76.
17. Renk H, Stoll L, Neunhoeffer F, et al. Suspicion of respiratory tract infection with multidrug-resistant Enterobacteriaceae: epidemiology and risk factors from a paediatric intensive care unit. BMC Infect Dis 2017; 17:163.
18. Costa Pde O, Atta EH, Silva AR. Infection with multidrug-resistant Gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes. J Pediatr (Rio J) 2015; 91:435–41.
19. Karsies TJ, Sargel CL, Marquardt DJ, et al. An empiric antibiotic protocol using risk stratification improves antibiotic selection and timing in critically ill children. Ann Am Thorac Soc 2014; 11:1569–75.
20. Pollack MM, Patel KM, Rattimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 1996; 24:743–52.
21. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol 2005; 58:475–83.
22. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med 2016; 35:214–26.
23. Willson DE, Conaway M, Kelly R, Hendley JO. The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children. Pediatr Crit Care Med 2014; 15:299–305.
24. de Mello MJ, de Albuquerque Mde F, Lacerda HR, et al. Risk factors for healthcare-associated infection in a pediatric intensive care unit. Pediatr Crit Care Med 2010; 11:246–52.
25. Mello MJ, Albuquerque Mde F, Lacerda HR, et al. Risk factors for healthcare-associated infection in pediatric intensive care units: a systematic review. Cad Saude Publica 2009; 25(Suppl 3):S373–91.
26. Toltzis P, Hoyen C, Spinner-Block S, et al. Factors that predict preexisting colonization with antibiotic-resistant Gram-negative bacilli in patients admitted to a pediatric intensive care unit. Pediatrics 1999; 103:719–23.
27. Morrow BM, Argent AC, Jeena PM, Green RJ. Guideline for the diagnosis, prevention and treatment of paediatric ventilator-associated pneumonia. S Afr Med J 2009; 99:255–67.
28. Baudel JL, Tankovic J, Carrat F, et al. Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality? Ther Clin Risk Manag 2009; 5:491–8.
29. Capp R, Chang Y, Brown DE. Effective antibiotic treatment prescribed by emergency physicians in patients admitted to the intensive care unit with severe sepsis or septic shock: where is the gap? J Emerg Med 2011; 41:573–80.
30. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010; 32:293–9.
31. Shorr AF, Bodi M, Rodriguez A, et al; CAPUCI Study Investigators. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006; 130:93–100.
32. Williams DJ, Edwards KM, Self WH, et al. Antibiotic choice for children hospitalized with pneumonia and adherence to national guidelines. Pediatrics 2015; 136:44–52.
33. Williams DJ, Hall M, Shah SS, et al. Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia. Pediatrics 2013; 132:e1141–8.
34. Ross RK, Hersh AL, Kronman MP, et al. Impact of Infectious Diseases Society of America/Pediatric Infectious Diseases Society guidelines on treatment of community-acquired pneumonia in hospitalized children. Clin Infect Dis 2014; 58:834–8.
35. Blinova E, Lau E, Bitnun A, et al. Point prevalence survey of antimicrobial utilization in the cardiac and pediatric critical care unit. Pediatr Crit Care Med 2013; 14:e280–8.
36. Leyenaar JK, Lagu T, Shieh MS, et al. Management and outcomes of pneumonia among children with complex chronic conditions. Pediatr Infect Dis J 2014; 33:907–11.
37. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103:e39.